ER-NEGATIVE BREAST CANCER
Clinical trials for ER-NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new ER-NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for ER-NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a smart drug cross the Blood-Brain barrier to attack breast cancer metastases?
Disease control Recruiting nowThis phase 2 trial is testing whether the investigational drug datopotamab deruxtecan (Dato-DXd) can safely and effectively treat HER2-negative breast cancer that has spread to the brain. The study enrolls adults with metastatic breast cancer who have brain metastases that are ei…
Matched conditions: ER-NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Nancy Lin, MD • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New drug combo aims to wipe out Triple-Negative breast cancer before surgery
Disease control Recruiting nowThis phase 2 study is testing a drug called sacituzumab govitecan, alone or with pembrolizumab, given before surgery to people with localized triple-negative breast cancer. The goal is to see if these drugs can eliminate all cancer cells in the breast and lymph nodes before surge…
Matched conditions: ER-NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC